RS50368B - Levodopa/karbidopa/entakapon farmaceutski preparat - Google Patents

Levodopa/karbidopa/entakapon farmaceutski preparat

Info

Publication number
RS50368B
RS50368B YUP-925/01A YUP92501A RS50368B RS 50368 B RS50368 B RS 50368B YU P92501 A YUP92501 A YU P92501A RS 50368 B RS50368 B RS 50368B
Authority
RS
Serbia
Prior art keywords
carbidopa
levodopa
entacapone
composition
pharmaceutical preparation
Prior art date
Application number
YUP-925/01A
Other languages
English (en)
Inventor
Sari Kallioinen
Lasse Kervinen
Marja Laaksonen
Jarmo Lintulaakso
Mervi Niskanen
Marja Partanen
Marja Ritala
Kari Vahervuo
Matti Virkki
Original Assignee
Orion Corporation,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8554988&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS50368(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corporation, filed Critical Orion Corporation,
Publication of YU92501A publication Critical patent/YU92501A/sh
Publication of RS50368B publication Critical patent/RS50368B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Čvrsta oralna kompozicija koja sadrži farmakološki delotvorne količine entakapona, levodopa i karbidopa, ili njihovih farmaceutski prihvatljivih soli ili hidrata, i farmaceutski prihvatljiv ekscipijent, naznačena time, što se bitan udeo karbidopa nalazi izdvojen od entakapona i levodopa, čime je postignuto terapijsko delovanje sa navedenom kompozicijom u lečenju Parkinsonove bolesti uporedivo sa onim postignutim sa poznatim odvojenim formulacijama entakapona i levodopa-karbidopa kad se jednovremeno administriraju pri istim dozama delotvornih sredstava kao u navedenoj oralnoj čvrstoj kompoziciji. Prijava sadrži još 25 patentnih zahteva.
YUP-925/01A 1999-06-30 2000-06-29 Levodopa/karbidopa/entakapon farmaceutski preparat RS50368B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI991485A FI109453B (fi) 1999-06-30 1999-06-30 Farmaseuttinen koostumus

Publications (2)

Publication Number Publication Date
YU92501A YU92501A (sh) 2004-09-03
RS50368B true RS50368B (sr) 2009-11-10

Family

ID=8554988

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-925/01A RS50368B (sr) 1999-06-30 2000-06-29 Levodopa/karbidopa/entakapon farmaceutski preparat

Country Status (42)

Country Link
US (2) US6500867B1 (sr)
EP (1) EP1189608B1 (sr)
JP (2) JP4204783B2 (sr)
KR (1) KR100905428B1 (sr)
CN (1) CN1168440C (sr)
AR (1) AR033796A1 (sr)
AT (1) ATE245417T1 (sr)
AU (1) AU765932B2 (sr)
BG (1) BG65364B1 (sr)
BR (2) BR0011867A (sr)
CA (1) CA2378469C (sr)
CO (1) CO5180579A1 (sr)
CZ (2) CZ303010B6 (sr)
DE (1) DE60004052T2 (sr)
DK (1) DK1189608T3 (sr)
EA (1) EA004503B1 (sr)
EE (1) EE05473B1 (sr)
ES (1) ES2203495T3 (sr)
FI (1) FI109453B (sr)
FR (1) FR2797587A1 (sr)
GE (1) GEP20043314B (sr)
HK (1) HK1047040B (sr)
HR (1) HRP20020088B1 (sr)
HU (1) HU230395B1 (sr)
IL (1) IL146807A (sr)
IT (1) ITMI20001450A1 (sr)
ME (1) ME00520B (sr)
MX (1) MXPA01013167A (sr)
MY (1) MY127685A (sr)
NO (2) NO330260B1 (sr)
NZ (1) NZ515780A (sr)
PE (1) PE20010399A1 (sr)
PL (1) PL197818B1 (sr)
PT (1) PT1189608E (sr)
RS (1) RS50368B (sr)
SI (1) SI1189608T1 (sr)
SK (1) SK286451B6 (sr)
TR (1) TR200103763T2 (sr)
TW (1) TWI241187B (sr)
UA (1) UA75047C2 (sr)
WO (1) WO2001001984A1 (sr)
ZA (1) ZA200109868B (sr)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20030224045A1 (en) * 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
US7094427B2 (en) * 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20040006072A1 (en) * 2002-06-25 2004-01-08 Franz Robert M. Sustained-release alprazolam composition
KR20050083750A (ko) * 2002-10-11 2005-08-26 디포메드 디벨롭먼트 리미티드 위-체류성 레보도파 전달 형태
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
US20060241183A1 (en) * 2004-09-28 2006-10-26 Farouk Karoum Compositions and methods of using D-DOPA to treat Parkinson's disease
JP2008519811A (ja) 2004-11-10 2008-06-12 オリオン コーポレーション 下肢静止不能症候群の治療
AU2012216377C1 (en) * 2005-06-08 2013-10-10 Orion Corporation Oral dosage form
EA013161B1 (ru) * 2005-06-08 2010-02-26 Орион Корпорейшн Дозированная форма для перорального применения
US20070003621A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Dosage forms for movement disorder treatment
MY148644A (en) 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
BRPI0613859B8 (pt) * 2005-07-26 2021-05-25 Bial Portela & Ca Sa inibidores da comt, seus usos, e composição farmacêutica
WO2007016190A2 (en) * 2005-07-28 2007-02-08 Duke University Antiparkinsonian action of phenylisopropylamines
WO2007034024A2 (en) * 2005-09-21 2007-03-29 Orion Corporation Treatment of symptoms of parkinson' s disease
WO2007056570A2 (en) * 2005-11-07 2007-05-18 Teva Pharmaceutical Industries Ltd. Levodopa compositions
WO2007069274A2 (en) * 2005-11-09 2007-06-21 Torrent Pharmaceuticals Limited Pharmaceutical composition comprising a compound having a catechol moiety and an alkalising agent
GB2429645A (en) * 2006-03-10 2007-03-07 Sekhsaria Chemicals Ltd Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent
CN100384411C (zh) * 2006-03-17 2008-04-30 北京科信必成医药科技发展有限公司 卡左双多巴口腔崩解片
WO2007113371A1 (en) * 2006-03-31 2007-10-11 Iprbox Oy Pharmaceutical composition and preparation method thereof
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
US8106056B2 (en) * 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
EP2104424A4 (en) 2006-10-30 2011-06-15 Wockhardt Research Center PHARMACEUTICAL COMPOSITIONS COMPRISING ENTACAPONE, LEVODOPA, AND CARBIDOPA
CA2673511A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
EP2114374A4 (en) * 2006-12-27 2011-03-23 Wockhardt Research Center PHARMACEUTICAL COMPOSITIONS OF ENTACAPONE
EP1946756A1 (en) * 2007-01-17 2008-07-23 Revotar Biopharmaceuticals AG Use of entacapone in cosmetic, dermatological and pharmaceutical compositions
EP2124947B1 (en) 2007-01-31 2017-07-19 BIAL - Portela & Ca., S.A. Dosage regimen for comt inhibitors
US20110171275A1 (en) * 2007-08-20 2011-07-14 Team Academy Of Pharmaceutical Science Gastroretentive drug delivery system, preparation method and use thereof
RU2010136934A (ru) * 2008-02-06 2012-03-20 Вокхард Рисерч Сентер (In) Фармацевтические композиции энтакапона, микронизированного с сахарными спиртами
JP5466179B2 (ja) * 2008-02-06 2014-04-09 ウォックハート リサーチ センター 生物学的利用能が改善されたエンタカポン、レボドパ及びカルビドパの医薬組成物
CA2718772C (en) 2008-03-17 2017-05-02 David Alexander Learmonth Crystal forms of 5-[3-(2,5-dichloro-4,6-dimethyl-1-oxy-pyridine-3-yl)[1,2,4]oxadiazol-5-yl]-3-nit robenzene-1,2-diol
UA102111C2 (uk) * 2008-08-22 2013-06-10 Вокхардт Рісерч Сентер Фармацевтична композиція у вигляді разової пероральної дози, що містить леводопу, карбідопу і ентакапон або їх солі
NZ591326A (en) * 2008-08-22 2012-12-21 Wockhardt Research Center An extended release pharmaceutical composition of entacapone or salts thereof
TR200806646A2 (tr) * 2008-09-03 2009-06-22 Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar
EP2233131A1 (en) 2009-03-23 2010-09-29 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa
CN105878242A (zh) 2009-04-01 2016-08-24 巴尔-波特拉及康邦亚股份有限公司 包括硝基儿茶酚衍生物的药物制剂及其制备方法
MX364974B (es) * 2009-05-19 2019-05-16 Neuroderm Ltd Composiciones para la administracion continua de inhibidores de dopa descarboxilasa.
JP5718937B2 (ja) * 2009-12-25 2015-05-13 イノファーマックス インコーポレイテッド パーキンソン病を治療するための医薬組成物及びその調製方法
EA026419B1 (ru) 2010-03-04 2017-04-28 Орион Корпорейшн Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона
DE102010023828A1 (de) * 2010-06-15 2011-12-15 IIP - Institut für industrielle Pharmazie, Forschungs- und Entwicklungsgesellschaft mbH Pharmazeutisches Präparat, welches Entacapon, Levodopa und Carbidopa enthält
WO2012066538A1 (en) 2010-11-15 2012-05-24 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
WO2012147099A1 (en) * 2011-04-25 2012-11-01 Suven Nishtaa Pharma Pvt. Ltd. Pharmaceutical compositions of levodopa, carbidopa and entacapone
EP2702991A4 (en) * 2011-04-26 2015-02-18 Innopharmax Inc COMPOSITION OF ENTACOPONE
PT3604299T (pt) 2011-12-13 2023-10-31 Bial Portela & Ca Sa Composto químico útil como intermediário para a preparação de um inibidor de catecol-o-metiltransferase
TR201204839A2 (tr) 2012-04-25 2012-12-21 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
EP3456315A1 (en) 2012-06-05 2019-03-20 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
CA2904838C (en) * 2013-03-13 2021-03-16 Neuroderm Ltd. Method for treatment of parkinson's disease
EP2799065A1 (en) * 2013-04-30 2014-11-05 Deva Holding Anonim Sirketi Levodopa carbidopa entacapone pharmaceutical formulations
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10098845B2 (en) 2013-10-07 2018-10-16 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
RS65060B1 (sr) 2014-03-13 2024-02-29 Neuroderm Ltd Sastavi inhibitora dopa dekarboksilaze
JP6622310B2 (ja) 2014-09-04 2019-12-18 ロブソル・ファーマシューティカルズ・アクチボラグＬｏｂｓｏｒ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ａｋｔｉｅｂｏｌａｇ レボドパ、ドーパミン脱炭酸酵素阻害薬およびｃｏｍｔ阻害薬を含む医薬組成物ならびにその投与方法
WO2016083863A1 (en) 2014-11-28 2016-06-02 Bial - Portela & Ca, S.A. Medicaments for slowing parkinson's disease
EP3236957A1 (en) 2014-12-23 2017-11-01 Pharmathen S.A. Levodopa/carbidopa/entacapone pharmaceutical preparation and method for preparing the same
US10555922B2 (en) 2015-09-04 2020-02-11 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
CN109689036A (zh) * 2016-07-11 2019-04-26 康特拉医药公司 用于治疗早晨运动不能的脉冲药物输送系统
WO2018034626A1 (en) 2016-08-18 2018-02-22 İlko İlaç Sanayi Ve Ticaret Anonim Şirketi Antiparkinson tablet formulation with improved dissolution profile
WO2019145773A1 (en) 2017-12-15 2019-08-01 Nos Life Sciences Corporation Liposomal-encapsulated formulations
WO2019182506A1 (en) 2018-03-23 2019-09-26 Lobsor Pharmaceuticals Aktiebolag Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190672A (en) 1978-09-01 1980-02-26 Stanley Fahn Method and compositions of treating Parkinsonisms with levodopa and 3',4'-dihydroxy-2-methylisopropiophenone
GB8521350D0 (en) * 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
US5283352A (en) 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB2321190B (en) 1997-01-16 2000-09-20 Britannia Pharmaceuticals Ltd Pharmaceutical composition
US6599530B2 (en) 1998-09-14 2003-07-29 Orion Corporation Oral compacted composition comprising catechol derivatives
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus

Also Published As

Publication number Publication date
AR033796A1 (es) 2004-01-07
NO20110090L (no) 2002-02-25
TWI241187B (en) 2005-10-11
IL146807A (en) 2006-10-05
FI991485A0 (fi) 1999-06-30
ES2203495T3 (es) 2004-04-16
AU765932B2 (en) 2003-10-02
CZ304416B6 (cs) 2014-04-23
EP1189608A1 (en) 2002-03-27
DE60004052D1 (de) 2003-08-28
EA004503B1 (ru) 2004-04-29
FI109453B (fi) 2002-08-15
US6797732B2 (en) 2004-09-28
PL197818B1 (pl) 2008-04-30
ITMI20001450A0 (it) 2000-06-28
AU5830600A (en) 2001-01-22
JP2008156373A (ja) 2008-07-10
ITMI20001450A1 (it) 2001-12-28
TR200103763T2 (tr) 2002-04-22
SI1189608T1 (en) 2004-04-30
CO5180579A1 (es) 2002-07-30
KR100905428B1 (ko) 2009-06-30
GEP20043314B (en) 2004-02-10
CN1358090A (zh) 2002-07-10
BRPI0011867B1 (pt) 2019-01-08
ZA200109868B (en) 2003-05-28
MXPA01013167A (es) 2002-07-02
CN1168440C (zh) 2004-09-29
EE200100716A (et) 2003-02-17
BG65364B1 (bg) 2008-04-30
SK286451B6 (sk) 2008-10-07
CA2378469A1 (en) 2001-01-11
HU230395B1 (hu) 2016-04-28
YU92501A (sh) 2004-09-03
DK1189608T3 (da) 2003-11-10
HK1047040B (zh) 2005-04-29
ATE245417T1 (de) 2003-08-15
KR20020010155A (ko) 2002-02-02
US6500867B1 (en) 2002-12-31
HRP20020088A2 (en) 2005-10-31
NO20016203D0 (no) 2001-12-18
SK19232001A3 (sk) 2002-06-04
MY127685A (en) 2006-12-29
BRPI0011867B8 (pt) 2021-05-25
EE05473B1 (et) 2011-10-17
EA200200106A1 (ru) 2002-06-27
PT1189608E (pt) 2003-12-31
HK1047040A1 (en) 2003-02-07
DE60004052T2 (de) 2004-04-15
WO2001001984A1 (en) 2001-01-11
PL352775A1 (en) 2003-09-08
JP4885896B2 (ja) 2012-02-29
EP1189608B1 (en) 2003-07-23
ME00520B (me) 2011-10-10
NZ515780A (en) 2004-06-25
HUP0202273A3 (en) 2002-11-28
FR2797587A1 (fr) 2001-02-23
CA2378469C (en) 2009-10-06
FI991485A (fi) 2000-12-31
HUP0202273A2 (en) 2002-10-28
NO20016203L (no) 2002-02-25
US20030017201A1 (en) 2003-01-23
BG106251A (en) 2002-08-30
BR0011867A (pt) 2002-03-05
CZ20014636A3 (cs) 2002-05-15
PE20010399A1 (es) 2001-04-10
JP4204783B2 (ja) 2009-01-07
CZ303010B6 (cs) 2012-02-29
JP2003503454A (ja) 2003-01-28
HRP20020088B1 (en) 2007-05-31
UA75047C2 (en) 2006-03-15
NO330260B1 (no) 2011-03-14

Similar Documents

Publication Publication Date Title
RS50368B (sr) Levodopa/karbidopa/entakapon farmaceutski preparat
YU49698A (sh) Smeše koje sadrže tetrahidrolipstatin
MEP33708A (en) Pharmaceutical compositions comprising a hmg coa reductase inhibitor
TR199500856A2 (tr) Nefesle ice cekilerek alinan farmasötik bilesim.
DK1623703T3 (da) Hydrocodonformuleringer med kontrolleret frigivelse
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
RS52922B (sr) Preparati za lečenje multiple skleroze i njihove upotrebe
LU91254I2 (fr) Daptomycine et ses dérivés pharmaceutiquement acceptables (cubicinr)
BRPI0108435B8 (pt) formulação e uso de entecavir de baixa dose
RS54050B1 (sr) Formulacije i metode za lečenje amiloidoze
YU49026B (sh) UPOTREBA 17 Гџ -(N-TERC-BUTILKARBAMOIL)-4-AZA-5-ALFA-ANDROST-1-3-ON ZA PROIZVODNJU LEKA ZA TRETIRANJE ANDROGENE ALOPECIJE
BG102857A (en) Antimycotic substance-containing and acetate buffer-containing compositions
EA200400007A1 (ru) ФАРМАЦЕВТИЧЕСКИЙ СОСТАВ ДЛЯ ЭФФЕКТИВНОГО ВВЕДЕНИЯ АПОМОРФИНА, 6aR-(-)-N-ПРОПИЛ-НОРАПОМОРФИНА, ИХ ПРОИЗВОДНЫХ И ИХ ПРОЛЕКАРСТВ
AR021806A1 (es) COMPOSICIoN FARMACÉUTICA EN FORMA DE TABLETA QUE COMPRENDE ENTACAPONA Y MÉTODO DE PREPARACIoN.
AP2003002763A0 (en) Controlled release formulations for oral administration
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
YU42397A (sh) Korišćenje raloksifena za pripremu leka
GEP20043227B (en) 5HT1 Antagonists for Antidepressant Therapy
GEP19991869B (en) Amino Acid Derivatives of Substituted Quinoxaline 2,3-Dione Derivatives as Glutamate Receptor Antagonists
BR0014440A (pt) Formulações de liberação controlada oral
BR0108313A (pt) Composição farmacêutica para injeção intramuscular contendo loxoprofeno
AU2173101A (en) Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents
TR199900013T2 (xx) Yeni bile�ikler.
GEP20053512B (en) S-Methyl-Dihydro-Ziprasidone for Treatment of Psychiatric and Ocular Disorders.
YU24603A (sh) Novi farmaceutski preparati koji sadrže epinastin i pseudoefedrin